Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 for Insulin Resistance
NCT01686568Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in insulin resistance (IR) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at 6 months. Started Dec 2012; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT01686568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01686568.